|
|
|
|
Stephen Willey
Vice President
Biotechnology
+1 212.271.3620
swilley@tweisel.com
Stephen Willey is a Vice President and follows the Biotechnology industry at Thomas Weisel Partners. He joined the firm in 2007 and is based in New York. Before joining Thomas Weisel Partners, he was a research scientist with ImClone Systems, where he worked in oncology drug discovery and pre-clinical drug development. Before that, he was a research associate at Mount Sinai School of Medicine, where he worked in both oncology and stem cell biology. Stephen received a BS degree from the University of New Hampshire, an MS degree from the University of Rhode Island and an MBA from New York University.
|
|
Coverage List
Ticker |
|
Company Name |
|
Rating |
|
Market Cap (mn) |
CBST |
|
Cubist Pharmaceuticals, Inc. |
|
Market Weight |
|
$1,346 USD |
IMCL |
|
ImClone Systems Incorporated |
|
Market Weight |
|
$5,553 USD |
ITMN |
|
InterMune, Inc. |
|
Overweight |
|
$729 USD |
MEDX |
|
Medarex, Inc. |
|
Market Weight |
|
$1,032 USD |
ONXX |
|
Onyx Pharmaceuticals |
|
Market Weight |
|
$2,397 USD |
OSIP |
|
OSI Pharmaceuticals, Inc. |
|
Overweight |
|
$2,957 USD |
PGLA |
|
Progen Pharmaceuticals Limited |
|
Overweight |
|
$34 USD |
VPHM |
|
ViroPharma Incorporated |
|
Overweight |
|
$951 USD |
|
|
